DGX Dec 2024 145.000 call
| Previous close | 7.93 |
| Open | 9.10 |
| Bid | 9.50 |
| Ask | 11.70 |
| Strike | 145.00 |
| Expiry date | 2024-12-20 |
| Day's range | 9.10 - 9.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 14 |
PR NewswireQuest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter, a seasoned technology executive, to serve as a director. Including Mr. Carter, the company's Board has 10 members.
PR NewswireQuest Diagnostics Declares Quarterly Cash Dividend
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics common stock on July 8, 2024.
- PR Newswire
Workforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics Drug Testing Index Analysis of Nearly 10 Million Drug Tests
The percentage of employees in the general U.S. workforce whose drug test showed signs of tampering increased by more than six-fold in 2023 versus the prior year, the highest rate ever in more than 30 years of annual reporting. This finding is part of a new analysis of nearly 9.8 million workforce drug tests released today by Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services. To view the full report, visit www.QuestDiagnostics.com/DTI.
